Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery

2014-08-27 03:12:16 | BioPortfolio


Protein Losing Enteropathy (PLE) is a serious and sometimes fatal medical condition that may develop in subjects with congenital cardiac disease for which a palliative procedure known as the "Fontan operation" is performed. The loss of protein through the intestine causes refractory hypoalbuminemia. Heparin administration has shown to improve PLE; however the risk of bleeding is important; this risk should be reduced by using ODSH instead of heparin. ODSH is a desulfated heparin with minimal anticoagulation properties. This open label study is to assess the safety and therapeutic evidence of the administration of ODSH as 4-day continuous intravenous infusion in patients with exacerbation of PLE.


Protein Losing Enteropathy (PLE)is a serious and sometimes fatal condition that develop in after single ventricle palliative surgery. The mechanisms are not well defined or understood; however a recent mechanism has been proposed consistent with the specific loss of heparin sulfate proteoglycans from the basolateral surface of the intestinal epithelial cells during PLE exacerbation. Heparin administration has improved this medical condition as reported in several cases in the medical literature with improvement or recovery of PLE exacerbations; however the risk of bleeding is high. ODSH ( 2-0, 3-0 desulfated heparin) is a modified heparin that preserves the anti-inflammatory properties of heparin with minimal or no anticoagulation effects. ODSH has been studied in the rodent model of PLE an has shown improvement of PLE due to restoration of heparan sulfate and Syndecan 1 with stabilization of the cell matrix of the capillary endothelium.

This open label study will enroll 9 subjects with a dose escalation (3 doses) study design. Three subjects will be treated with the lower dose of ODSH then an ad hoc safety committee will assess the safety information to recommend on advancing to the next higher dose of ODSH; until the 3 dose cohorts are completed. Plasma albumin and fecal alpha 1 antitrypsin; both biological markers of protein loss through the intestinal lumen in this condition, are the primary variables studied. The effect of ODSH on the associated diarrhea, abdominal pain, and peripheral edema or ascitis will also be evaluated using visual/categorical scales for the patients to assess symptoms and clinical evaluation by the investigator.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Exacerbation of Protein Losing Enteropathy


ODSH ( 2-0, 3-0 desulfated heparin)


Department of Cardiology, Children's Hospital Boston
United States





Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:12:16-0400

Clinical Trials [1007 Associated Clinical Trials listed on BioPortfolio]

Characterizing the Effect of Dopamine on Markers of Lymph Re-circulation in Fontan-associated Protein-losing Enteropathy

Patients that have undergone a Fontan procedure (surgical correction for single ventricle congenital heart disease) may develop a complication known as protein-losing enteropathy (PLE). So...

A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD

The purpose of this study is to determine whether ODSH, when added to conventional treatment, is more effective in treating COPD exacerbations than conventional therapy alone.

Enteropathy and Diabetes in HIV Patients

Emerging data suggest that HIV-infected people have disproportionately higher risk of diabetes than HIV-uninfected people. Multiple factors may contribute to elevated diabetes risk includi...

Heparin Induced Thrombocytopenia: Pharmacoeconomics

Patients at BWH receiving unfractionated heparin or enoxaparin who subsequently develop heparin induced thrombocytopenia will be identified via a computer generated report designed for the...

Heparin Responses in Pediatric Patients Undergoing Cardiopulmonary Bypass.

Heparin is an anticoagulant or "blood thinner". Heparin is always given to patients undergoing open-heart surgery to prevent blood from clotting when a patient is placed on the heart-lung ...

PubMed Articles [9732 Associated PubMed Articles listed on BioPortfolio]

A Rare Complication of Giardiasis in Children: Protein-losing Enteropathy.

Protein-losing enteropathy may develop as a complication of a wide spectrum of diseases. Three cases of giardiasis that presented with acute onset of hypoalbuminemia were documented, and resolution of...

A man with recurrent hypovolemic shock on anti-programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy.

A case report of a young adult with progressive bloody diarrhea, protein losing enteropathy and extended polyposis coli.

Partial small intestinal resection for successful surgical management of refractory protein-losing gastroenteropathy in systemic lupus erythematosus: A case report and literature review.

Although systemic lupus erythematosus (SLE) can be complicated by various gastrointestinal tract diseases, it is rarely associated with lupus enteritis and protein-losing enteropathy (PLE). We report ...

Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia.

Heparin-induced thrombocytopenia (HIT) is an adverse reaction to heparin characterized by thrombocytopenia and thrombotic complications. HIT is caused by pathogenic antibodies that bind to complexes o...

Medical and Biotech [MESH] Definitions

Pathological conditions in the INTESTINES that are characterized by the gastrointestinal loss of serum proteins, including SERUM ALBUMIN; IMMUNOGLOBULINS; and at times LYMPHOCYTES. Severe condition can result in HYPOGAMMAGLOBULINEMIA or LYMPHOPENIA. Protein-losing enteropathies are associated with a number of diseases including INTESTINAL LYMPHANGIECTASIS; WHIPPLE'S DISEASE; and NEOPLASMS of the SMALL INTESTINE.

A sulfated plasma protein with the MW of approximately 66kDa that resembles ANTITHROMBIN III. The protein is an inhibitor of thrombin in plasma and is activated by dermatan sulfate or heparin. It is a member of the serpin superfamily.

A syndrome characterized by chronic, well-established DIARRHEA (greater than one month in duration) without an identified infectious cause after thorough evaluation, in an HIV-positive individual. It is thought to be due to direct or indirect effects of HIV on the enteric mucosa. HIV enteropathy is a diagnosis of exclusion and can be made only after other forms of diarrheal illness have been ruled out. (Harrison's Principles of Internal Medicine, 13th ed, pp1607-8; Haubrich et al., Bockus Gastroenterology, 5th ed, p1155)

Coagulant substances inhibiting the anticoagulant action of heparin.

A heparin fraction with a mean molecular weight of 4500 daltons. It is isolated from porcine mucosal heparin and used as an antithrombotic agent. (From Merck Index, 11th ed)

More From BioPortfolio on "Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery"

Quick Search


Relevant Topics

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Palliative Care
Palliative care is the active holistic care of patients with advanced progressive illness. Management of pain and other symptoms and provision of psychological, social and spiritual support is paramount. The goal of palliative care is achievement of the ...

Searches Linking to this Trial